Impaired glucose tolerance during pregnancy that does not meet the criteria for gestational diabetes nevertheless increases the likelihood that women will later develop type 2 diabetes, a study shows.
A health informatics system based on routine clinical data helps physicians to prioritize high-risk people with diabetes, deliver more equitable care, and manage healthcare capacity, report researchers.
There is a “substantial” burden of overweight and obesity among people with type 1 diabetes, say US researchers who found rates to be in line with that of the general population.
Allowing people to trial medications for type 2 diabetes and choose their preferred one is a viable approach in the absence of a clear clinical indication.
A meta-analysis published in The Lancet supports the use of SGLT2 inhibitors in people with chronic kidney disease, irrespective of whether they have type 2 diabetes.
People with type 1 diabetes who take GLP-1 receptor agonists or SGLT2 inhibitors in clinical practice have outcomes that are mostly – but not all – in line with those in controlled trials, say researchers.
The strength of the association between diabetes and the risk for cardiovascular events has lessened over recent years, report researchers.
Findings from a nationally representative US survey show that a substantial minority of people with diabetes ration their use of insulin because of issues with affordability.
Researchers calculate that the price of SGLT2 inhibitors and GLP-1 receptor agonists would need to fall “by at least 70%” to make them cost effective first-line treatments in the USA.
People with type 2 diabetes and chronic kidney disease are substantially less likely to initiate SGLT2 inhibitors than those with normal kidney function, despite their proven renoprotective benefits, research shows.